Skip to content

RFA-TR-25-002 Rare Disease R21 Eligibility Guide

Updated 7 official sources

Quick Answer: RFA-TR-25-002 is an NCATS R21 for rare disease preclinical proof-of-concept studies.

Full answer and how we checked it

It funds efficacy testing in an established model, allows pharmacodynamic and pharmacokinetic work, disallows clinical trials, and caps direct costs at $275,000 over two years. The 2026 decision turns on 7 checks.

Who this is for: Rare disease researchers, translational therapeutics teams, small biotechs, academic drug-discovery groups, animal-model teams, and sponsored-research offices deciding whether a preclinical R21 is enough before IND-enabling work.

Data note: This guide uses NIH RFA-TR-25-002, NIH NOT-TR-26-009, Grants.gov listing 357570, and NIH RePORTER award records checked on October 10, 2026.

In this guide

RFA-TR-25-002 is not a rare disease idea grant. NIH says it funds efficacy studies in an established rare disease preclinical model to show that a proposed therapeutic agent warrants further development. The route is about proof for a therapeutic agent, not building the model from scratch.

Use this guide with the live Rare Disease Preclinical R21 program record. Then compare NIH grants complete guide, NIH R01 R21 R03 K awards comparison, what is a NOFO, Maternal and Pediatric Pharmacology R21 guide, and the Grantsights grant database.

October 2026 Source Status

RFA-TR-25-002 is open for one more round. The original June 2, 2026 due date has passed. On June 5, 2026, NCATS issued NOT-TR-26-009 (opens in a new tab), extending the RFA by one council round: the remaining due date is June 2, 2027 for new and resubmission applications, and the RFA now expires June 3, 2027.

Current factOctober 10, 2026 applicant read
Opportunity numberRFA-TR-25-002
Clinical trial statusNot allowed
Remaining due dateJune 2, 2027 (5 p.m. local time)
Expiration dateJune 3, 2027
Budget cap$275,000 direct costs over 2 years, no more than $200,000 in one year
Review timeline for the June 2, 2027 roundScientific merit review October 2027, advisory council January 2028, earliest start April 2028
Award planThe RFA's stated set-aside (up to $1.2 million and 3 to 5 awards) was for FY2026; NOT-TR-26-009 doesn't state a separate amount for the extra round
Nonresponsive riskModel development, rare cancer route, no named therapeutic agent, or clinical trial design

Get grant deadline alerts by email

About once a week, we email a short list of open grant calls with real deadlines from different funders. It isn't limited to the programs in this guide.

No spam. Unsubscribe anytime.

7 RFA-TR-25-002 Eligibility Stop Checks

Within 21 days, use this section as the checkpoint for rare disease preclinical proof before a team commits to the R21 route.

7 stop checks decide whether this route fits.

Stop checkStrong R21 signalRed flag
Rare diseaseFewer than 200,000 people in the U.S. or orphan status evidenceDisease prevalence is not documented
ModelEstablished model is ready nowProposal asks to develop the model
Therapeutic agentAgent is named and testableDiscovery screen is still open-ended
EfficacyPreclinical efficacy endpoint is definedEndpoint is only descriptive
PK/PDPharmacodynamic or pharmacokinetic work supports the proofExposure and response are disconnected
Trial statusNo clinical trialHuman intervention assignment is planned
Next stepIND or trial-readiness route is plausibleNo development path after award

If the model is not ready, the route is probably wrong. If the agent is not ready, the route is probably too late-stage for the current team.

5 Source Facts Applicants Should Know

Within 21 days, use this section as the checkpoint for rare disease preclinical proof before a team commits to the R21 route.

5 facts should appear before the applicant commits to drafting.

FactSource-backed read
Funding numberRFA-TR-25-002
MechanismR21 Exploratory/Developmental Research Grant
Clinical trial statusNot allowed
BudgetUp to $275,000 direct costs over 2 years
Remaining due dateJune 2, 2027, with June 3, 2027 expiration

The RFA says NIH intended up to $1.2 million in FY2026 for 3 to 5 awards, contingent on meritorious applications and funding, and that money went to the first round. The extension notice, NOT-TR-26-009, only adds the June 2, 2027 due date, with merit review in October 2027, council in January 2028, and an earliest start of April 2028. It doesn't set aside a new amount or award count, so an applicant in the remaining round should treat funding as dependent on FY2028 budgets. According to USAspending.gov (opens in a new tab) data, assistance listing 93.350 had about $588.2M in FY2024 obligations across 731 awards active that year.

What NIH Doesn't Tell You

Within 21 days, use this section as the checkpoint for rare disease preclinical proof before a team commits to the R21 route.

4 practical issues decide whether the R21 is worth pursuing.

First, rare disease proof needs prevalence evidence. The application should cite prevalence or orphan status and show why the selected disease belongs here.

Second, the model has to be established. NIH says applications requesting support for development of the rare disease model are not responsive. That means model validation cannot be left for the award.

Third, rare cancers are a bad fit. NIH directs rare cancer applicants to NCI preclinical therapeutics contacts.

Fourth, the R21 should create an investment-grade next step. NIH frames the goal around moving projects toward later investment, IND application development, or clinical-trial progression for repurposing or repositioning.

What NCATS Funded in FY2026

Grantsights checked NIH RePORTER (opens in a new tab) on October 10, 2026 and found 8 FY2026 awards under RFA-TR-25-002, more than the 3 to 5 the RFA anticipated. Every award was made by NCATS, and first-year total costs ran from $415,250 to $462,000. Half were funded on resubmission (A1), so a first-round miss isn't the end of the road.

AwardOrganizationAgent and disease
1R21TR006182-01UT Southwestern Medical CenterAAV9 gene replacement for PDHA1 deficiency in a mouse model
1R21TR005230-01A1Oregon Health & Science UniversityAAV gene therapy for Alport syndrome in a dog model
1R21TR005505-01A1University of GeorgiaRepurposed alpelisib for multiple hereditary exostoses
1R21TR005180-01A1Children's Mercy Hospital, Kansas CityEverolimus for Vici syndrome
1R21TR006184-01University of MinnesotaNervonic acid for cerebral demyelination in adrenoleukodystrophy
1R21TR006115-01Columbia University Health SciencesInsulin receptor agonists for congenital severe insulin resistance

The other two went to Stanford and Mount Sinai. Grantsights analysis of the 8 award titles in NIH RePORTER (opens in a new tab) shows each one names a specific agent and, in several cases, the model species. That's the readiness reviewers are asked to judge.

What Reviewers Weigh and What Gets an Application Pulled

According to RFA-TR-25-002 (opens in a new tab), reviewers are asked to evaluate the strength of evidence that the model is relevant to the disease, the biological rationale linking the target to the disease, and whether the agent is ready to be tested for efficacy in vivo or in an advanced in vitro system. The RFA says the approach may not be novel; reviewers judge whether it moves the field toward a therapeutic that's a substantial improvement over, or distinct from, what exists.

Two rules can stop an application before review:

  • The Research Strategy must include a paragraph headed "Evidence Supporting Rare Disease Classification" with prevalence references (200,000 or fewer U.S. patients) and FDA orphan status if granted. Leaving it out makes the application non-responsive.
  • Foreign subawards aren't allowed. Applications with foreign subawards or subcontracts will be deemed noncompliant, though unfunded collaborations and foreign consultants are still permitted.

6 Evidence Assets That Make This R21 Stronger

Within 21 days, use this section as the checkpoint for rare disease preclinical proof before a team commits to the R21 route.

6 evidence assets make the route stronger. The first is a disease classification memo with prevalence, orphan status if relevant, unmet need, and disease biology.

The second is an established model dossier. Include model type, construct validity, face validity if relevant, prior use, phenotype, reproducibility, and limitations.

The third is a therapeutic-agent summary. Name the agent type, rationale, dose range, delivery route, prior data, manufacturability issues, and safety signals.

The fourth is an efficacy endpoint table. It should separate primary proof endpoints from supportive biomarkers.

The fifth is a PK/PD plan. A rare disease efficacy signal is weaker if exposure and response are not connected.

The sixth is a development path. A team should be able to say what happens after the R21: IND-enabling studies, SBIR/STTR, industry license, R01, or stop.

5 Route Choices Before Drafting

Within 21 days, use this section as the checkpoint for rare disease preclinical proof before a team commits to the R21 route.

5 route choices should be compared.

RouteBetter first read when...Why
RFA-TR-25-002 R21Established model and therapeutic agent are readyRoute matches proof stage
Parent R21Rare disease route is closed or not specific enoughActive NIH path may fit
SBIR/STTRCompany-led development is centralProduct route may fit better
NCI preclinical routeRare cancer is the focusNIH says rare cancer applicants should seek NCI guidance
IND-enabling pathProof is already strongR21 may be too early

Many teams shouldn't draft this R21 until the model and agent are ready.

6 Bad-Fit Signals

Within 21 days, use this section as the checkpoint for rare disease preclinical proof before a team commits to the R21 route.

6 bad-fit signals should be visible early. First, the project does not clearly address a rare disease. Second, the proposal asks to develop the model. Third, the disease is a rare cancer.

Fourth, the therapeutic agent is not ready to test. Fifth, the project includes a clinical trial. Sixth, the R21 result would not support a concrete next development decision.

21-Day Preclinical Proof Plan

Within 21 days, use this section as the checkpoint for rare disease preclinical proof before a team commits to the R21 route.

Days 1 through 3 should confirm source status, due date, clinical-trial status, and budget.

Days 4 through 7 should build the rare disease memo: prevalence, orphan status if relevant, unmet need, disease biology, and target rationale.

Days 8 through 12 should audit the model. If the model is not established, stop and choose another path.

Days 13 through 16 should define the therapeutic-agent proof table: dose, route, timing, endpoints, PK/PD, safety, and failure threshold.

Days 17 through 21 should map the next route. The R21 should produce a go, no-go, license, SBIR/STTR, IND-enabling, or R01 decision.

7 Above-the-Fold Claims That Need Proof

Within 21 days, the first screen should prove 7 claims: what the route funds, whether the source is open or expired, whether clinical trials are allowed, what budget rule applies, who is eligible in practice, what does not fit, and what route should be compared next.

According to NIH in the NOFO (opens in a new tab), this source should be treated as the authority for rules.

7 Route Checks

Added June 2, 2026.

Checked on June 2, 2026 against RFA-TR-25-002 (opens in a new tab), the Grants.gov listing (opens in a new tab), USASpending.gov (opens in a new tab), Grants.gov (opens in a new tab), and USASpending.gov (opens in a new tab).

CheckPublic answer
EligibilityConfirm the applicant, institution, and route rules for RFA-TR-25-002 rare disease preclinical R21 eligibility.
Source statusVerify the official listing, notices, due date, and expiration status.
BudgetCheck award size, cost limits, match, or budget logic when the source provides it.
EvidenceName the data, preliminary work, partner role, or implementation proof needed.
Bad fitStop if the project belongs in a nearby NIH or federal route.
Review criteriaTie the first page to significance, approach, team, environment, and source-specific criteria.
Next actionDecide whether to draft, ask a program contact, or redirect to a nearby route.

Final public checklist

  • Confirm whether R21 is the right route or whether a nearby program fits better.
  • Check budget, partner, match, or data-readiness constraints.

Sources

Next steps

Where to go next

These next pages help you move from research into a specific grant choice.

Frequently Asked Questions

What does RFA-TR-25-002 fund?

It funds efficacy studies in an established rare disease preclinical model to show that a therapeutic agent warrants further development.

Are clinical trials allowed?

No. RFA-TR-25-002 is clinical trial not allowed.

What budget applies?

NIH caps direct costs at $275,000 over two years, with no more than $200,000 in any single year.

What is the next deadline?

NIH extended RFA-TR-25-002 under NOT-TR-26-009; the current application due date is June 2, 2027, and the opportunity expires June 3, 2027.

Who should skip this route?

Skip it if the project develops the disease model, targets a rare cancer, lacks a therapeutic agent, or includes a clinical trial.

Last updated October 12, 2026. Corrected October 11, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.